Healthcare Sector
Market Tracker
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 04/17/2026 | PUT | $11.00 | 170 | +60 | +54.55% |
| 04/17/2026 | CALL | $17.00 | 3 | +2 | +200.00% |
| 12/18/2026 | CALL | $10.00 | 13 | +2 | +18.18% |
| 04/17/2026 | PUT | $15.00 | 211 | +1 | +0.48% |
| 04/17/2026 | CALL | $2.50 | 0 | 0 | |
| 04/17/2026 | CALL | $4.00 | 0 | 0 | |
| 12/18/2026 | PUT | $20.00 | 0 | 0 | |
| 12/18/2026 | PUT | $22.00 | 0 | 0 | |
| 12/18/2026 | PUT | $25.00 | 0 | 0 | |
| 12/18/2026 | PUT | $27.00 | 0 | 0 | |
| 12/18/2026 | PUT | $30.00 | 0 | 0 | |
| 04/17/2026 | CALL | $10.00 | 67 | -1 | -1.47% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.34% | 922.53k | 9.57M |
| Vanguard Small-Cap Index Fund | 2.10% | 825.39k | 8.56M |
| iShares Russell 2000 ETF | 1.61% | 633.59k | 6.57M |
| Vanguard Small-Cap Growth Index Fund | 1.21% | 475.49k | 4.93M |
| Franklin Strategic Series-Franklin Small Cap Growth Fund | 1.09% | 427.5k | 4.43M |
| Vanguard Extended Market Index Fund | 0.92% | 360.62k | 3.74M |
| iShares Russell 2000 Value ETF | 0.77% | 302.37k | 3.14M |
| Avantis U.S. Small Cap Value ETF | 0.73% | 287.21k | 2.98M |
| Fidelity Small Cap Index Fund | 0.64% | 253.23k | 2.63M |
| iShares NASDAQ Biotechnology ETF | 0.60% | 236.28k | 2.45M |
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
09/12 07:00 am
GlobeNewswire Inc.
Read moreCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
08/07 07:00 am
GlobeNewswire Inc.
Read moreCullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
04/16 07:00 am
GlobeNewswire Inc.
Read moreCullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
02/27 08:00 am
GlobeNewswire Inc.
Read moreCullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
11/14 11:01 am
GlobeNewswire Inc.
Read moreAmgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
09/25 08:04 am
Benzinga
Read moreCullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
09/14 04:15 am
GlobeNewswire Inc.
Read moreCullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
06/01 07:00 am
GlobeNewswire Inc.
Read moreCullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
05/24 08:00 am
GlobeNewswire Inc.
Read moreCullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
05/23 05:04 pm
GlobeNewswire Inc.
Read moreCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
05/15 04:05 pm
GlobeNewswire Inc.
Read moreCullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
04/29 07:00 am
GlobeNewswire Inc.
Read moreWhy Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
04/24 02:29 pm
Benzinga
Read moreCullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
04/24 10:09 am
GlobeNewswire Inc.
Read moreUnited Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
04/17 10:55 am
Benzinga
Read moreCullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
04/16 01:32 pm
Benzinga
Read moreUnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
04/16 10:15 am
Benzinga
Read moreCullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
03/14 07:00 am
GlobeNewswire Inc.
Read moreOcuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
03/04 09:18 am
Zacks Investment Research
Read moreCullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
03/01 08:00 am
GlobeNewswire Inc.
Read morePuma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
02/27 12:51 pm
Zacks Investment Research
Read moreAvalo (AVTX) to Report Q4 Earnings: What's in the Cards?
02/26 12:28 pm
Zacks Investment Research
Read moreSarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
02/21 12:24 pm
Zacks Investment Research
Read morePerrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
02/20 02:32 pm
Zacks Investment Research
Read moreModerna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?
02/19 12:01 pm
Zacks Investment Research
Read moreCullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/18 05:53 pm
GlobeNewswire Inc.
Read moreCullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
12/14 05:30 pm
GlobeNewswire Inc.
Read moreCullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
11/03 12:01 pm
GlobeNewswire Inc.
Read moreBenzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
10/06 11:00 am
Benzinga
Read moreCullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
08/10 07:00 am
GlobeNewswire Inc.
Read moreAnalyst Ratings for Cullinan Oncology
08/09 02:00 pm
Benzinga
Read moreCullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
08/09 07:00 am
GlobeNewswire Inc.
Read moreCullinan Oncology to Participate in Upcoming Investor Conferences
07/31 08:00 am
GlobeNewswire Inc.
Read moreAnalyst Ratings for Cullinan Oncology
07/07 08:04 am
Benzinga
Read moreAnalyst Expectations for Cullinan Oncology's Future
06/15 04:01 pm
Benzinga
Read moreBenzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
06/15 11:01 am
Benzinga
Read moreExpert Ratings for Cullinan Oncology
06/15 08:01 am
Benzinga
Read more4 Analysts Have This to Say About Cullinan Oncology
05/26 09:02 am
Benzinga
Read moreCullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
05/25 05:00 pm
GlobeNewswire Inc.
Read moreCullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
04/26 10:08 am
GlobeNewswire Inc.
Read moreCullinan: Trading Way Below Cash
04/05 01:28 am
Seeking Alpha
Read moreWhat 4 Analyst Ratings Have To Say About Cullinan Oncology
03/27 12:00 pm
Benzinga
Read moreCullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
03/27 07:00 am
GlobeNewswire Inc.
Read moreCullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
03/14 04:35 pm
GlobeNewswire Inc.
Read moreCelularity (CELU) to Report Q4 Earnings: What's in the Cards?
03/06 11:54 am
Zacks Investment Research
Read more